<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01845818</url>
  </required_header>
  <id_info>
    <org_study_id>P13-990</org_study_id>
    <nct_id>NCT01845818</nct_id>
  </id_info>
  <brief_title>Study in Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA) Patients to Evaluate Work Productivity Before and After the Start of Adalimumab Therapy in Daily Practice in Belgium</brief_title>
  <acronym>SPACTIVE</acronym>
  <official_title>Observational Study in AS and PsA Patients to Evaluate Work Productivity Before and After the Start of Adalimumab Therapy in Daily Practice in Belgium</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This observational study will document to what extend in daily clinical practice the work
      productivity is affected before and after the start of adalimumab treatment.

      Changes in the employment status and work productivity of patients with AS and PsA before and
      after the start of Adalimumab will be noted. The relationship between employment status, work
      productivity, disease activity and clinical evaluations will be evaluated. Since AS and PsA
      might be very invalidating diseases with a strong impact on the daily life of the patient, an
      evaluation will be performed to the effect of the disease on Quality of Life and work
      productivity.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 5, 2013</start_date>
  <completion_date type="Actual">June 23, 2017</completion_date>
  <primary_completion_date type="Actual">June 23, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in total work productivity impairment due to ankylosing spondylitis and psoriatic arthritis</measure>
    <time_frame>From Day 0 to 18 months</time_frame>
    <description>18 months versus baseline in all patients, measured by the Work Productivity and Activity Impairment-Specific Health Problem questionnaire. (Patient reported outcome)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in evolution of employment status and work productivity after initiation of adalimumab treatment between ankylosing spondylitis and psoriatic arthritis patients throughout the study, measured by Work Productivity and Activity Impairment</measure>
    <time_frame>From Day 0 to 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution over time of work productivity: (observed for ankylosing spondylitis and psoriatic arthritis combined and separately): Number of patients that are employed at each assessed visit</measure>
    <time_frame>up to 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Related Quality of Life - Health Assessment Questionnaire - Disability Index - Patient reported outcome (psoriatic arthritis)</measure>
    <time_frame>up to 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease activity measures and clinical evaluations - Body Surface Area - psoriatic arthritis</measure>
    <time_frame>up to 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Related Quality of Life - Dermatology Life Quality Index - Patient reported outcome (psoriatic arthritis)</measure>
    <time_frame>up to 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Related Quality of Life - Health Assessment Questionnaire modified for spondyloarthropathies - Patient reported outcome (ankylosing spondylitis)</measure>
    <time_frame>up to 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease activity measures and clinical evaluations - Disease Activity Score 28 - Psoriatic arthritis</measure>
    <time_frame>up to 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease activity measures and clinical evaluations - Bath Ankylosing Spondylitis Disease Activity Index - ankylosing spondylitis</measure>
    <time_frame>Up to 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease activity measures and clinical evaluations - Acute phase reactants (C-Reactive Protein / Erythrocyte Sedimentation Rate)</measure>
    <time_frame>up to 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease activity measures and clinical evaluations - Visual Analogue Scale</measure>
    <time_frame>up to 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution over time of work productivity:(observed for ankylosing spondylitis and psoriatic arthritis combined and separately): Percentage of missed working hours (absenteeism) due to ankylosing spondylitis/psoriatic arthritis 7 days prior to each visit</measure>
    <time_frame>up to 18 months</time_frame>
    <description>The Work Productivity and Activity Impairment- Specific Health Problem, a validated questionnaire for the self-assessment of work productivity and activity impairment with reference to a specific health problem, is used. All dimensions relate to the past seven days. Scores are transformed into percentages. Higher scores indicate greater impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution over time of work productivity:(observed combined and separately):Assessment of the effect of ankylosing spondylitis or psoriatic arthritis on the ability to do regular daily activities during the 7 days prior to each visit(activity impairment)</measure>
    <time_frame>up to 18 months</time_frame>
    <description>The Work Productivity and Activity Impairment- Specific Health Problem, a validated questionnaire for the self-assessment of work productivity and activity impairment with reference to a specific health problem, is used. All dimensions relate to the past seven days. Scores are transformed into percentages. Higher scores indicate greater impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution over time of work productivity: (observed combined and separately): Assessment of the effect of ankylosing spondylitis or psoriatic arthritis on productivity while working during the 7 days prior to each visit (presenteeism)</measure>
    <time_frame>up to 18 months</time_frame>
    <description>The Work Productivity and Activity Impairment- Specific Health Problem, a validated questionnaire for the self-assessment of work productivity and activity impairment with reference to a specific health problem, is used. All dimensions relate to the past seven days. Scores are transformed into percentages. Higher scores indicate greater impairment.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">183</enrollment>
  <condition>Ankylosing Spondylitis</condition>
  <condition>Psoriatic Arthritis</condition>
  <arm_group>
    <arm_group_label>Patients with Ankylosing Spondylitis and Psoriatic Arthritis</arm_group_label>
    <description>Patients with Ankylosing Spondylitis and Psoriatic Arthritis and in whom adalimumab treatment is initiated. All medication will be prescribed in the usual manner in accordance with the terms of the marketing authorization and in line with the Belgian reimbursement criteria.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Ankylosing Spondylitis and Psoriatic Arthritis followed in university or
        peripheral hospitals or peripheral private practices with experience in Ankylosing
        Spondylitis and Psoriatic Arthritis care.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient &gt;= 18 years and &lt;= 50 years

          -  Patient diagnosed with Ankylosing Spondylitis or Psoriatic Arthritis

          -  Patient to be initiated on Adalimumab (according to the Marketing Authorization and
             Belgian reimbursement criteria)

          -  Patient willing to sign Informed Consent

        Exclusion Criteria:

          -  Any contraindication for Adalimumab as specified in the corresponding SmPC

          -  Patient previously treated with biologics

          -  Patient participating in other AbbVie-sponsored trials
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Simonne Lens, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie sa</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Onze Lieve Vrouw Hospital /ID# 99196</name>
      <address>
        <city>Aalst</city>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Linda Marx, Amel, Belgium /ID# 105396</name>
      <address>
        <city>Amel</city>
        <zip>4770</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imelda Ziekenhuis /ID# 118995</name>
      <address>
        <city>Bonheiden</city>
        <zip>2820</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Sint Jan Brugge /ID# 99199</name>
      <address>
        <city>Bruges</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHIREC (Clin. Parc Leopold) /ID# 105375</name>
      <address>
        <city>Brussels</city>
        <zip>1040</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CUB Hospital Erasme /ID# 105378</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopitaux Iris Sud /ID# 99136</name>
      <address>
        <city>Brussels</city>
        <zip>1190</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rhumarc /ID# 99224</name>
      <address>
        <city>Ceroux-Mousty</city>
        <zip>1341</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Laurence Dujardin, Ciney, Belgium /ID# 99221</name>
      <address>
        <city>Ciney</city>
        <zip>5590</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen /ID# 99135</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Anne-Marie Jeugmans, Flemalle, Belgium /ID# 99219</name>
      <address>
        <city>Flemalle</city>
        <zip>4400</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Xavier Van Mullem, Forchies-la Marche, Belgium /ID# 99218</name>
      <address>
        <city>Forchies-la-Marche</city>
        <zip>6141</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reumacentrum /ID# 99202</name>
      <address>
        <city>Genk</city>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grand Hopital de Charleroi /ID# 99195</name>
      <address>
        <city>Gilly</city>
        <zip>6060</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Martin Maertens, Gistel, Belgium /ID# 99201</name>
      <address>
        <city>Gistel</city>
        <zip>8470</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Muriel Moris, Heist-op-den-Berg, Belgium /ID# 105397</name>
      <address>
        <city>Heist-op-den-Berg</city>
        <zip>2220</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Ste. Elisabeth /ID# 105379</name>
      <address>
        <city>Heusy</city>
        <zip>4802</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Sart Tilman /ID# 99138</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Geert Ghyselen, Lokeren, Belgium /ID# 99215</name>
      <address>
        <city>Lokeren</city>
        <zip>9160</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Johan Waes, Mechelen, Belgium /ID# 99222</name>
      <address>
        <city>Mechelen</city>
        <zip>2800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Geert Stappaerts, Merelbeke, Belgium /ID# 99225</name>
      <address>
        <city>Merelbeke</city>
        <zip>9820</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Militair Ziekenhuis Neder-over-Heembeek /ID# 105377</name>
      <address>
        <city>Neder-Over-Heembeek</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Ruth Reychler, Oudenaarde, Belgium /ID# 99216</name>
      <address>
        <city>Oudenaarde</city>
        <zip>9700</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Delta /ID# 99139</name>
      <address>
        <city>Roeslare</city>
        <zip>8800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Alma Campus Sijsele /ID# 99197</name>
      <address>
        <city>Sijsele</city>
        <zip>8340</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Nancy Van den Bossche, Sint Niklaas, Belgium /ID# 105376</name>
      <address>
        <city>Sint-Niklaas</city>
        <zip>9100</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Turnhout Campus Sint-Jozef /ID# 99198</name>
      <address>
        <city>Turnhout</city>
        <zip>2300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Nathalie Sarlet, Verviers, BE /ID# 105380</name>
      <address>
        <city>Verviers</city>
        <zip>4800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCL Mont Godinne /ID# 131516</name>
      <address>
        <city>Yvoir</city>
        <zip>5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>http://www.rxabbvie.com</url>
  </link>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 1, 2013</study_first_submitted>
  <study_first_submitted_qc>May 1, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2013</study_first_posted>
  <last_update_submitted>July 6, 2017</last_update_submitted>
  <last_update_submitted_qc>July 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>work productivity</keyword>
  <keyword>multicenter study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Spondylitis, Ankylosing</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

